Results 151 to 160 of about 60,702 (193)

An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria.

International Immunopharmacology, 2022
BACKGROUND Guidelines recommend standard doses of antihistamines as first-line, and updosing of antihistamines as second-line treatment for the management of chronic urticaria (CU).
Sinem Ayse Ornek, Cihan Orcen, M. Church, E. Kocaturk   +3 more
semanticscholar   +1 more source

Lachnospira is a signature of antihistamine efficacy in chronic spontaneous urticaria

Experimental Dermatology, 2021
Chronic spontaneous urticaria (CSU) is a mast cell‐driven disease with many advances in its aetiology and pathogenesis over the past years. The main treatment of CSU is oral second‐generation antihistamines.
Runqiu Liu, C. Peng, D. Jing, Yangjian Xiao, Wu Zhu, Shuang Zhao, Jiang-Lin Zhang, Xiang Chen, Jie Li   +8 more
semanticscholar   +1 more source

Antihistamine Premedication Improves Safety and Efficacy of Allergen Immunotherapy.

Annals of Allergy, Asthma & Immunology, 2021
BACKGROUND Allergen immunotherapy (AIT)-associated adverse events are a major concern for safety and efficacy of AIT. Presently, there is no consensus to whether antihistamine premedication could improve such conditions.
Li Wang, Cheng-Shuo Wang, H. Lou, Luo Zhang   +3 more
semanticscholar   +1 more source

Intranasal antihistamine is superior to oral H1-antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis.

Annals of Allergy, Asthma & Immunology, 2020
BACKGROUND Currently a combination of intranasal corticosteroid (INCS) plus oral H1antihistamines (OAH) or intranasal H1-antihistamines (INAH) therapy is frequently used in the treatment of allergic rhinitis (AR).
Kun Du, Hui Qing, M. Zheng, Xiangdong Wang, Luo Zhang   +4 more
semanticscholar   +1 more source

Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1‐antihistamine treatment: results of the phase IV open‐label SUNRISE study

British Journal of Dermatology, 2018
Omalizumab is approved as an add‐on therapy for the treatment of chronic spontaneous urticaria (CSU) in patients with inadequate response to H1‐antihistamine treatment.
F. Berard, M. L. le Bouëdec, L. Bouillet, Z. Reguiai, A. Barbaud, F. Cambazard, B. Milpied, B. Pelvet, I. Kasujee, H. Gharbi, J. Lacour   +10 more
semanticscholar   +1 more source

Effect of the H1-antihistamine clemastine on PACAP38 induced migraine

Cephalalgia, 2018
Objective To investigate the effect of the H1-antihistamine clemastine on the migraine-inducing abilities of pituitary adenylate cyclase activating peptide-38.
Luise Haulund Vollesen, Song Guo, M. Andersen, M. Ashina   +3 more
semanticscholar   +1 more source